<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550418</url>
  </required_header>
  <id_info>
    <org_study_id>BUX-3/UCA</org_study_id>
    <nct_id>NCT02550418</nct_id>
  </id_info>
  <brief_title>Budesonide 9 mg Capsules in Active UC</brief_title>
  <acronym>TOPICAL-1</acronym>
  <official_title>Open-label, Multi-centre, Proof of Concept Phase IIa Clinical Trial on the Efficacy and Tolerability of an 8 Week Oral Treatment With Once Daily 9 mg Budesonide in Patients With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to evaluate the efficacy of an 8 week treatment with once-daily 9
      mg budesonide in patients with active ulcerative colitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinical remission at final/withdrawal visit</measure>
    <time_frame>8 weeks treatment</time_frame>
    <description>Clinical remission includes normalisation of stool frequency and absence of blood in stools</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of endoscopic remission/improvement at final/withdrawal visit</measure>
    <time_frame>8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of stools / bloody stools per week</measure>
    <time_frame>8 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <arm_group_label>Budesonide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent,

          -  Men or women aged 18 to 75 years,

          -  Active ulcerative colitis, except proctitis limited to 15 cm ab ano, confirmed by
             endoscopy and histology,

          -  Established disease,

        Exclusion Criteria:

          -  Crohn's disease, indeterminate colitis, ischaemic colitis, radiation colitis,
             microscopic colitis (i.e., collagenous colitis and lymphocytic colitis, incomplete
             microscopic colitis), diverticular disease associated colitis,

          -  Toxic megacolon or fulminant colitis,

          -  Colon resection,

          -  Evidence of infectious colitis (e.g., pathogenic bacteria or Clostridium difficile
             toxin in stool culture at screening),

          -  Malabsorption syndromes,

          -  Celiac disease,

          -  Bleeding hemorrhoids,

          -  Active peptic ulcer disease

          -  Other inflammatory or bleeding disorders of the colon and intestine, or diseases that
             may cause diarrhea or gastrointestinal bleeding,

          -  Hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma,
             cataract, or infection if careful medical monitoring is not ensured,

          -  Any severe infectious disease (e.g., tuberculosis, AIDS),

          -  Severe co-morbidity substantially reducing life expectancy,

          -  History of colorectal cancer,

          -  History of cancer (other than colorectal) in the last 5 years, except for basal cell
             carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Fellermann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Schleswig-Holstein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Schleswig-Holstein</name>
      <address>
        <city>LÃ¼beck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

